The introduction of imaging agents targeting prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein that is overexpressed on PC cells [2,3], has further improved the ability to detect and ascertain the presence of metastatic disease compared to conventional imaging [4], showing high diagnostic accuracy for primary staging and restaging during biochemical recurrence [5,6,7]. This evidence concerns the gene FOLH1 and metastatic neoplasm.